RxDoctor Payments Data

Ann Esquivel, MD

Allergy & Immunology · Zionsville, INNPI 1457642597

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $6,300 of the $7,859 with a category attached, or 80.2%. Teva Pharmaceuticals USA, Inc. accounts for 83.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2021 at $6,657 and has fallen 95.9% since, to $272 in 2025.

$7,859in general payments, 2019–2025

Across 73 payments — averaging $107.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$7K
  • GSK$227
  • AstraZeneca$179
  • CSL Behring$106
  • Sanofi$101
  • Amgen$85
  • plus $606 from 16 others

What the payments were for

  • Speaking & faculty fees$6,30080%
  • Food & beverage$1,50119%
  • Education$571%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,859 in reported general payments places this provider in the 65th percentile of 49 allergy & immunology providers in Indiana.

See all allergy & immunology providers in Indiana

Medicare billing

Part B allowed, 2024
$110,186
Medicare patients
131
Services billed
7,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab12$41,320
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$23,466
Breo ElliptaFluticasone/Vilanterol21$13,148
Epinephrine67$9,923
SymbicortBudesonide/Formoterol Fumarate33$9,832
Arnuity ElliptaFluticasone Furoate34$9,143
DuleraMometasone/Formoterol17$5,751
Advair HfaFluticasone Propion/Salmeterol16$5,731
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$5,667
Pulmicort FlexhalerBudesonide12$3,524
Ipratropium Bromide85$2,602
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$2,532
Albuterol Sulfate HfaAlbuterol Sulfate63$2,291
Montelukast Sodium217$1,755
Fluticasone Propionate96$1,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta$227$87,07790 claims
AstraZenecaSymbicort, Pulmicort Flexhaler$179$13,35645 claims
MerckDulera$16$5,75117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 49 allergy & immunology providers in Indiana.

Other allergy & immunology in Zionsville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →